A5016510706- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Viral-associated cancers and disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Retinoids in leukemia and cellular processes
- Immunodeficiency and Autoimmune Disorders
- CNS Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- HIV/AIDS drug development and treatment
- Protein Degradation and Inhibitors
- Cancer Genomics and Diagnostics
- Epigenetics and DNA Methylation
- MicroRNA in disease regulation
- Peptidase Inhibition and Analysis
- Blood groups and transfusion
- Platelet Disorders and Treatments
- T-cell and Retrovirus Studies
- Blood disorders and treatments
- Childhood Cancer Survivors' Quality of Life
- Multiple and Secondary Primary Cancers
Institut Català d'Oncologia
2014-2024
Hospital Universitari Joan XXIII de Tarragona
2015-2024
Universitat Rovira i Virgili
2002-2024
Institut d'Investigació Sanitària Pere Virgili
2009-2017
Hospital de Sant Pau
2008-2014
Universitat Autònoma de Barcelona
2013
Fundación Pethema
2005-2009
Hospital Arnau de Vilanova
2009
Centro de Investigación del Cáncer
2008
Hospital Universitario Ramón y Cajal
2008
Complete response (CR) is considered an important goal in most hematologic malignancies. However, multiple myeloma (MM), there no consensus regarding whether immunofixation (IF)-negative CR, IF-positive near-CR (nCR), and partial (PR) are associated with different survivals. We evaluated the prognostic influence on event-free survival (EFS) overall (OS) of these responses pre- post-transplantation newly diagnosed patients MM.We analyzed 632 from prospective Grupo Español de Mieloma 2000...
Minimal residual disease (MRD) is an important prognostic factor in adults with acute lymphoblastic leukemia (ALL) and may be used for treatment decisions. The Programa Español de Tratamientos en Hematología (PETHEMA) ALL-AR-03 trial (Treatment of High Risk Adult Acute Lymphoblastic Leukemia [LAL-AR/2003]) assigned adolescent adult patients (age 15 to 60 years) high-risk ALL (HR-ALL) without the Philadelphia (Ph) chromosome chemotherapy or allogeneic hematopoietic stem-cell transplantation...
Genome studies of diffuse large B-cell lymphoma (DLBCL) have revealed a number somatic mutations and structural alterations. However, the clinical significance these alterations is still not well defined. In this study, we integrated analysis targeted next-generation sequencing 106 genes genomic copy (CNA) in 150 DLBCL. The clinically significant findings were validated an independent cohort 111 patients. Germinal center activated DLBCL had differential profile mutations, altered pathogenic...
The presence of circulating plasma cells in patients with multiple myeloma is considered a marker for highly proliferative disease. In the study herein, impact assessed by cytology on survival was analyzed. Wright-Giemsa stained peripheral blood smears 482 newly diagnosed or cell leukemia were reviewed and classified into 4 categories according to percentage cells: 0%, 1–4%, 5–20%, following frequencies: 382 (79.2%), 83 (17.2%), 12 (2.5%) 5 (1.0%), respectively. Median overall group 47, 50,...
It has been recognized that cure is possible for human immunodeficiency virus (HIV)-infected patients with Burkitt lymphoma/leukemia (BL) if appropriate chemotherapy used. The introduction of rituximab in BL therapeutic schemes scarcely explored. outcome and toxicity HIV-positive treated a intensive chemotherapy-based trial was evaluated.Thirty-six consecutive patients, 15 to 55 years age, diagnosed advanced stage were recruited from July 2003 August 2006, stratified according HIV infection...
The addition of monoclonal antibodies to chemotherapy has significantly improved treatment chronic lymphocytic leukemia (CLL). Based on excellent results with the chemotherapy-only regimen fludarabine, cyclophosphamide, and mitoxantrone (FCM), we built a new chemoimmunotherapy combination--rituximab plus FCM (R-FCM). We report phase II clinical trial consisting an initial R-FCM followed by rituximab maintenance.Seventy-two untreated CLL patients age 70 years or younger received 500 mg/m(2)...
Fludarabine, cyclophosphamide, and mitoxantrone (FCM) results in a high response rate previously treated patients with chronic lymphocytic leukemia (CLL). The aim of this study was to investigate FCM as frontline therapy CLL.Sixty-nine under the age 65 years active CLL were treated. Patients received six cycles fludarabine 25 mg/m(2) i.v. x 3 days, cyclophosphamide 200 6 1 day. Treatment outcome correlated clinical biological variables. significance eradicating minimal residual disease (MRD)...
Background The aim of this study was to compare the long-term safety and efficacy oral busulfan 12 mg/kg plus melphalan 140 mg/m2 200 as conditioning regimens for autologous stem cell transplantation in newly diagnosed patients with multiple myeloma GEM2000 study.Design Methods first 225 received mg/m2; because a high frequency veno-occlusive disease, protocol amended further 542 mg/m2.Results Engraftment hospitalization times were similar both groups. Oral resulted higher transplant-related...
// Marina Díaz-Beyá 1, 2 , Salut Brunet 2, 3 Josep Nomdedéu 4 Marta Pratcorona Anna Cordeiro 5 David Gallardo 6 Lourdes Escoda 7 Mar Tormo 8 Inmaculada Heras 9 Maria Ribera 10 Rafael Duarte 11 María Paz Queipo de Llano 12 Joan Bargay 13 Antonia Sampol 14 Meritxell Nomdedeu 1 Ruth M. Risueño Montserrat Hoyos Jorge Sierra Mariano Monzo Alfons Navarro 5, * Jordi Esteve 15, on behalf of the Cooperative AML group CETLAM Hematology Department, Hospital Clinic,...
The genetic mechanisms associated with splenic marginal zone lymphoma (SMZL) transformation are not well defined. We studied 41 patients SMZL that eventually underwent large B-cell transformation. Tumor material was obtained either only at diagnosis (9 patients), and (18 (14 patients). Samples were categorized in 2 groups: (1) (SMZL, n = 27 samples), (2) (SMZL-T, 32 samples). Using copy number arrays a next-generation sequencing custom panel, we identified the main genomic alterations SMZL-T...
Abstract Mantle cell lymphoma (MCL) is a mature B‐cell neoplasm with an aggressive behavior, characterized by the t(11;14)(q13;q32). Several secondary genetic abnormalities potential role in oncogenic process have been described. Studies of large MCL series using conventional cytogenetics, and correlating proliferation survival, are scarce. We selected 145 cases at diagnosis, displaying aberrant karyotype, from centers belonging to Spanish Cooperative Group for Hematological Cytogenetics....
Some copy number alterations (CNAs) have independent prognostic significance for adults with acute lymphoblastic leukemia (ALL).This study analyzed via multiplex ligation-dependent probe amplification the frequency and impact of CNAs 12 genetic regions in 142 adolescents de novo precursor B-cell ALL.The cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) deletion (59 or 42%) was most frequent CNA, it followed by Ikaros family zinc finger 1 (IKZF1) losses (49 35%). IKZF1 deletions were more...
Abstract The 2017 European LeukemiaNet (ELN 2017) guidelines for the diagnosis and management of acute myeloid leukemia (AML) have become fundamental to assess prognosis postremission therapy patients. However, they been retrospectively validated in few studies with patients included different treatment protocols. We analyzed 861 Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mielodisplasias-12 risk-adapted protocol, which indicates cytarabine-based consolidation allocated...
Most patients with acute myeloid leukemia (AML) and genetic rearrangements involving the core binding factor (CBF) have favorable prognosis. In contrast, a minority of them still high risk recurrence. This study investigated adverse features CBF AML that could justify investigational therapeutic approaches.One hundred fifty (median age 42 yr, range 16-69) (RUNX1-RUNX1T1 n = 74; CBFB-MYH11 76) were prospectively enrolled into two consecutive CETLAM protocols at 19 Spanish institutions. Main...